
Tezspire Achieves Both Primary Goals in Phase III WAYPOINT Trial for Chronic Rhinosinusitis with Nasal Polyps
AstraZeneca and Amgen announced promising top-line results from the Phase III WAYPOINT trial, showing that Tezspire (tezepelumab) significantly reduced nasal polyp size and congestion in patients with chronic rhinosinusitis with…












